CMPX

Compass Therapeutics, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Anderman JonathanGeneral Counsel
$47k25k shares
BuyApr 29, 2026
$1.89
--
Lerner NeilChief Accounting Officer
$28k15k shares
BuyApr 29, 2026
$1.89
--
Schuetz Thomas J.Director, Officer: CHIEF EXECUTIVE OFFICER
$21k10k shares
BuyMay 27, 2025
$2.11
--
Gordon Carl LDirector, 10 Percent Owner:
$5.7M3.6M shares
SellApr 9, 2025
$1.59
--
Orbimed Advisors LLCDirector, 10 Percent Owner:
$5.7M3.6M shares
SellApr 9, 2025
$1.59
--
Anderman JonathanGen Counsel & Corporate Sec
$31k20k shares
BuyApr 7, 2025
$1.54
--

News

seekingalpha.comCompass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 9marketbeat.comCompass Therapeutics Eyes FDA Path After Tovecimig Trial Winmarketbeat.comJun 8globenewswire.comCompass Therapeutics to Participate in Upcoming June Investor Eventsglobenewswire.comMay 28globenewswire.comCompass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meetingglobenewswire.comMay 21gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPXgurufocus.comMay 21